Status:

UNKNOWN

Bioequivalence of Ezetimibe Tablets in Healthy Subjects

Lead Sponsor:

Cao Yu

Conditions:

Therapeutic Equivalency

Eligibility:

All Genders

18+ years

Phase:

PHASE1

Brief Summary

According to the relevant provisions of bioequivalence test, ezetimibe Tablets (test preparation, T, 10mg / tablet) provided by China Resources Saike Pharmaceutical Co., Ltd. were compared with Ezetro...

Eligibility Criteria

Inclusion

  • Healthy male or female subjects ≥18 years of age, with appropriate sex ratio;
  • The body mass index is in the range of 19.0-26.0 kg/m2 (including the critical value). The weight of male is not less than 50.0 kg, and that of female is not less than 45.0 kg.
  • The following examination show that the indicators are normal or abnormal without clinical significance. The examination including: Vital signs, physical examination, blood routine, blood biochemistry, urinalysis, pregnancy test for female, serological tests for hepatitis B virus, hepatitis C virus, human immunodeficiency virus (HIV), and syphilis virus, 12 lead ECG, breath test for alcohol, drug abuse test and Nicotine test.
  • The subjects have no family planning within 3 months and could select contraceptive method.
  • Before the study, all subjects have been informed of the study's purpose, protocal, benefits, and risks, and signed the informed consent voluntarily.

Exclusion

  • Alanine aminotransferase \>1.0×ULN ,Aspartate aminotransferase \>1.0×ULN or Total bilirubin \>1.0×ULN.
  • Subjects with allergic constitution.
  • Being allergy to the study medications, smoking, alcohol abuse.
  • Participation in another clinical trial within 3 months.

Key Trial Info

Start Date :

March 13 2021

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

July 31 2021

Estimated Enrollment :

96 Patients enrolled

Trial Details

Trial ID

NCT04814589

Start Date

March 13 2021

End Date

July 31 2021

Last Update

March 24 2021

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Phase Ⅰ Clinical Research Center

Qingdao, Shandong, China, 266003

Bioequivalence of Ezetimibe Tablets in Healthy Subjects | DecenTrialz